drugset / Trial / NCT00003821

Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer

NCT00003821

Phase 2 Withdrawn Genzyme, a Sanofi Company
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory or recurrent endometrial cancer.

Timeline

Start
1998-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject aminopterin Small molecule Oral

Indications